Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance
Our study, presented at ASCO 2024, investigated the use of AI-based software to assess PD-L1 expression in gastric cancer. The AI demonstrated a higher agreement with pathologists than pathologists with each other, while classifying more patients as eligible for immunotherapy.
Specifically, the AI showed a higher correlation and better concordance (+15%, p<0.05) in classifying patients than pathologists. Overall, the AI detected over 50% more positive cases (46 vs. 30.3), suggesting that the application of AI could help identify more patients eligible for targeted PD-L1 therapy.
Read more: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2633
You may also be interested in
Find out more about our AI-based diagnostics
